🔗 Permalink

Assignee profile:

Apoxis S.A.

City:

Epalinges

Country:

Switzerland

Published Applications:

Last publication date:

2011-06-30

Patent Grants:

Last grant date:

2013-08-06

Top Inventors for applications by Apoxis S.A.

These are the the leading inventors for applications assigned to Apoxis S.A.:

Jurg TSCHOPP 7 Epalinges, Switzerland
Catherine Hession 4 Hingham, MA United States
Pascal SCHNEIDER 3 Epalinges, Switzerland
Olivier Gaide 2 Lausanne, Switzerland

Virginie Petrilli 1 Lausanne, Switzerland
Christine Ambrose 1 Reading, MA United States
Thibaut De Smedt 1 Lutry, Switzerland
Jeffrey Thompson 1 Stoneham, MA United States

Schneider Pascal 1 Epalinges, Switzerland
Paul Rennert 1 Millis, MA United States
Fabio Martinon 1 Lausanne, Switzerland
MacKay Fabienne 1 Vaucluse, Australia

Rene Goedkoop 1 Bogis Bossey, Switzerland
Tschopp Jurg 1 Epalinges, Switzerland
Stéphane Demotz 1 Epalinges, Switzerland
Ambrose Christine 1 Reading, MA United States

Olivier GAIDE 1 Geneva, Switzerland
Browning Jeffrey 1 Brookline, MA United States
Thompson Jeffrey 1 Stoneham, MA United States
Marc Dupuis 1 Blonay, Switzerland

Teresa Cachero 1 Brookline, MA United States

Recent patent applications by Apoxis S.A.

Apoxis S.A. based in Epalinges, CH has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2011-06-30

US20110158993A1

Chemistry; metallurgy

Train-R: A Cysteine Rich Member of the TNF-Receptor Family

#2 | 2010-10-07 ✅ Patent 8,501,177 granted on 2013-08-06

US20100254984A1

Human necessities

Treatment of ectodermal dysplasia with EDA1 fusion proteins

#3 | 2010-04-06 ✅ Patent 7,691,804 granted on 2010-04-06

US10077137

BAFF receptor (BCMA), an immunoregulatory agent

#4 | 2009-01-01 ✅ Patent 7,838,639 granted on 2010-11-23

US20090004188A1

Chemistry; metallurgy

Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor

#5 | 2008-01-03

US20080003226A1

Chemistry; metallurgy

Method to Reduce Hepatoxicity of Fas-Mediated Apoptosis-Inducing Agents

#6 | 2007-10-02 ✅ Patent 7,276,241 granted on 2007-10-02

US10115192

Methods of treating a tumor that expresses APRIL by administering BCMA

#7 | 2007-07-12

US20070161559A1

Human necessities

METHOD FOR THE TREATMENT OF GOUT OR PSEUDOGOUT

#8 | 2007-05-29 ✅ Patent 7,223,852 granted on 2007-05-29

US10303502

Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family

#9 | 2006-10-19 ✅ Patent 7,402,658 granted on 2008-07-22

US20060233792A1

Chemistry; metallurgy

TRAIN-R: a cysteine-rich member of the TNF-receptor family

#10 | 2005-07-14 ✅ Patent 7,736,657 granted on 2010-06-15

US20050152872A1

Human necessities

Fusion constructs containing active sections on TNF ligands

AssigneeID:

203720 ⎘